Arvinas, Inc. (ARVN)
$34.16
Rating:
Recommendation:
-
| Symbol | ARVN |
|---|---|
| Price | $34.16 |
| Beta | 1.940 |
| Volume Avg. | 0.62M |
| Market Cap | 1.880B |
| Shares () | - |
| 52 Week Range | 13.57-39.31 |
| 1y Target Est | - |
| DCF Unlevered | ARVN DCF -> | |
|---|---|---|
| DCF Levered | ARVN LDCF -> | |
| ROE | -58.36% | Strong Sell |
| ROA | -27.53% | Sell |
| Operating Margin | - | |
| Debt / Equity | 0.87% | Neutral |
| P/E | -6.19 | Strong Sell |
| P/B | 4.04 | Strong Buy |
Latest ARVN news
About
Download (Excel)Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.